selectivity and sensitivity, and it was the subject of a recent international workshop 39, . The consensus of that meeting was that LAI testing offered a promising adjunct to currently available diagnostic and monitoring procedures in cancer patients, having the essential attributes of specificity and correlation with clinical course. (Ilearly there is a need for f-Lirther study to evaltiate the usefulness of this assay.
In this paper we report the results of a series of tests carried out using the technique of Grosser & Thomson (1,975) on blood samples taken from 44 women at first presentation to the cliiiic with s-Lispected breast disease. An essential feature of this trial was that the diagnosis of the disease was unknown at the time of testing, being confirmed 1-3 weeks later by clinical examination, mammography and histology. A realistic assessment of the immunodiagnostic value of LAI should therefore be possible by comparison with standard screening procedures. The sample was supplemented with blood from 7 healthy hospital personnel, making a total Accepted 8 August 1979 of 51 women. Of the women presenting at the clinic, 5 presented with breast pain but showed no abnormality. Malignancy was confirmed in 18 individuals, the majority being infiltrating duct carcinoma, one of which was considered advanced; histoloLyv revealed a medullary carcinoma in one case, and a lobular carcinoma in another. Twenty-one patients showed benign lesions, including 9 cysts, 6 fibroadenosis, 3 fibrocystic disease, I lipoma, I calcification. and I duct ectasia.
The LAI assay was pe orformed in tubes using the method described by Grosser & Thomson (1975) but with the following differences: antigens were prepared from 2 breast carcinomas using a sample of normal kidney as control, whereas Grosser tivity in the test group. All assays were performed at that value (180 pg/ml final concentration in the tubes). Grosser & Thomson (1975) indicate that protein concentrations of 100-440 /-tg/ml are discriminatory, and later studies more frequently use concentrations of -I 00 jug/ ml (Lopez et al., 1978) . Samples were recoded before the counting of nonadherent cells by an independent operator. Results are expressed as a non-adherence index --"(NAI), which was calculated as indicatq, d in Table 1 . An arbitrary cut-off of NAI = 25 was taken, since 95 % of healthy individuals tested gave NAI < 25. Examples of the assay results are presented in the Table and the data from the entire series are depicted in the Figure. Positive reactivity (NAI > 25) occurred in 8/18 (44%) breast-cancer patients and 9/21 (43%) patients with benign lesions. Only one healthy individual showed a positive NAI. Among the patients with breast disease no particular histology showed high reactivity and no relationship was found to any known prognostic or predisposing factor. In our hands the LAI test has, therefore, failed to provide a meaningful adjunct to the currently available diagnostic techniques, although different reactions were apparent between individuals both with and without breast disease.
Two major points distinguish our results from those of previous studies of LAI in breast disease:
(1) A lower proportion (43%) of breast-cancer patients have been shown to be reactive than in several other studies, in which the response rate was generally above 60% (Grosser & Thomson, 1975; Fritze el al., 1978; Lopez et al., 1978) . This could not be related to the stage of disease (localized disease) or 11 (regional lymph node metastases). It seems likely that extracts may vary in their ability to inhibit adherence, although a second extract used in parallel with the present study showed entirely comparable activity (data not shown). The use of pooled extracts may facilitate increased rates of tumour detection .
(2) The high incidence of positive reactions in unselected outpatients presenting with benign disease has not previously been reported. Lopez et al. (I 9 7 8) indicated a false-positive rate of between 2 and .1 2 % depending on disease severity whilst Sanner et al. (1979) found a mean response rate of 24%, with some selectivity (up to 43% positive) for patients in high risk groups. The reasons for our disparate results remain unclear. The observation of cross-reactivity between benign and malignant diseases is, however, in accord with several studies using migration inhibition assays (LMI) in stomach (Z611er et al., -1.977), colon (Burtin et al., 1978) and lung (Vose et al., 1977) . Indeed crossreactivity in breast diseases has been described in both cytotoxicity and LMI assays (Avis et al., 1974; Cannon et al., 1.978) . The LAI assay has also failed to distinguish benign from malignant liver disorders (Dusheiko et al., 1979) . Taken together, these data suggest that liyperplasia or tissue breakdown associated with disease may induce response to a range of normal organ-related antigens in such a way that the detection of tumourspecific reactivity by assays of CMI may be seriously compromised. If such a con-c1usion is.correct, extracts of normaland malignant breastfissue should give similar patterns of reactivity. This has not been shown (Grosser & Thomson, 1975; Fritze et al., 1978) , although it is difficult to obtain appropriate control material. Sensitization to normal antigens would account for the frequently observed organspecific patterns of reactivity in malignant disease. The nature of the reactivity must then remain unresolved. It is clear that this assay has, in some laboratories, considerable discriminatory powers. The results of the present study suggest that the test is not easily exploitable in the routine examination of patients, a view in accord'%i,ith that of Lopez et al., 1978. Tli's study was supported by grants from the Medical Research Council and Cancer Researcii Campaign. We are gratefi-il to Michael Moore for discussion and critical reading of the manuscript an(i to Professor R. A. Sellwood for permission to investigate patients under Iiis care.
